New Prostate Cancer Book Answers Patients' Queries

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

NEW YORK--Marion Morra, associate director of the Yale Cancer Center, has collaborated with her sister Eve Potts, a medical writer for more than 30 years, to produce The Prostate Cancer Answer Book: An Unbiased Treatment Guide, published in September by Avon Books to coincide with Prostate Cancer Awareness Month.

NEW YORK--Marion Morra, associate director of the Yale CancerCenter, has collaborated with her sister Eve Potts, a medicalwriter for more than 30 years, to produce The Prostate CancerAnswer Book: An Unbiased Treatment Guide, published in Septemberby Avon Books to coincide with Prostate Cancer Awareness Month.

The authors take all the most frequently asked questions aboutthe disease and give answers in plain language, based on the mostup-to-date information available in 1996. With an 8-point checklist of things to do, they walk the patient through the stepsneeded to make a decision about treatment.

The co-authors have written three other books for the lay audience:Choices: The Cancer Sourcebook; Triumph: Getting Back to NormalWhen You Have Cancer; and Understanding Your Immune System.In 1993, they received the Natalie Davis Springarn Writer's Awardfrom the National Coalition for Cancer Survivors for their booksChoices and Triumph.

In his foreword to the prostate cancer book, Vincent DeVita, MD,director of the Yale Cancer Center, writes that "it is difficultfor the public to understand how doctors can disagree on treatmentsfor prostate cancer, but we do, and our conflicts are often coloredby the biases we acquire in training. . . . Lots of things arehappening, most of them good, that are changing how prostate canceris understood and treated."

The book is available from Avon Trade Paperbacks for $12.50.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content